Clinical Trials in San José, Costa Rica
17 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL
Merck Sharp & Dohme LLC290 enrolled121 locationsNCT05139017
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled294 locationsNCT06868277
Recruiting
Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC868 enrolled229 locationsNCT06077760
Recruiting
Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Cancer
Hoffmann-La Roche100 enrolled57 locationsNCT05862285
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled258 locationsNCT06312176
Recruiting
Not Applicable
Feasibility Study of an Accommodating IOL Design
Aphakia
Alcon Research85 enrolled5 locationsNCT07147192
Recruiting
Not Applicable
Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma
OAG - Open-Angle Glaucoma
New World Medical, Inc.70 enrolled3 locationsNCT05696561
Recruiting
Not Applicable
Motiva Flora® Aesthetic Breast Recon® Clinical Study
Breast CancerMammaplastyPoland Syndrome
Establishment Labs66 enrolled4 locationsNCT06146231
Recruiting
A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm
Aortic Stenosis
World Health Research Inc.290 enrolled21 locationsNCT06991517
Recruiting
Not Applicable
Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit Early Feasibility Study
Peripheral Artery Occlusive Disease
Xeltis6 enrolled1 locationNCT06951685
Recruiting
PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
Breast Cancer Female
International Agency for Research on Cancer3,000 enrolled13 locationsNCT03144648
Recruiting
Not Applicable
Motiva Flora Tissue Expander PMCF
Breast CancerBreast Tissue Accessory
Establishment Labs136 enrolled5 locationsNCT05447988
Recruiting
Not Applicable
LatAm-FINGERS Initiative for Cognitive Change
Alzheimer Disease
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia1,200 enrolled13 locationsNCT06492967